Kinnate Biopharma Inc. to Post Q3 2023 Earnings of Per Share, HC Wainwright Forecasts
KNTEDelisted Stock | USD 2.96 0.27 8.36% |
About 61% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
Kinnate |
Kinnate Biopharma Inc. Analysts at HC Wainwright lifted their Q3 2023 earnings estimates for Kinnate Biopharma in a research report issued to clients and investors on Tuesday, September 19th. HC Wainwright analyst R. Burns now expects that the company will earn per share for the quarter, up from their
Read at thelincolnianonline.com
Kinnate Biopharma Fundamental Analysis
We analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Kinnate Biopharma is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Kinnate Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kinnate Biopharma stock to make a market-neutral strategy. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with similar companies.
Peers
Kinnate Biopharma Related Equities
IPSC | Century Therapeutics | 20.74 | ||||
KRON | Kronos Bio | 10.34 | ||||
SRZN | Surrozen | 8.96 | ||||
WINT | Windtree Therapeutics | 8.93 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
LRMR | Larimar Therapeutics | 7.44 | ||||
GLUE | Monte Rosa | 5.93 | ||||
ERAS | Erasca | 5.04 | ||||
BOLT | Bolt Biotherapeutics | 5.00 | ||||
KROS | Keros Therapeutics | 2.02 | ||||
STOK | Stoke Therapeutics | 1.19 | ||||
PALI | Palisade Bio | 0.83 | ||||
EWTX | Edgewise Therapeutics | 0.37 | ||||
KZR | Kezar Life | 0.40 | ||||
GBIO | Generation Bio | 0.69 | ||||
SLRN | ACELYRIN, INC | 1.51 | ||||
DSGN | Design Therapeutics | 2.93 | ||||
PASG | Passage Bio | 10.67 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Bonds Directory Find actively traded corporate debentures issued by US companies |